极性蛋白Par3参与肝癌发生发展的分子机制研究
结题报告
批准号:
81772615
项目类别:
面上项目
资助金额:
55.0 万元
负责人:
陈舌
依托单位:
学科分类:
H1809.肿瘤复发与转移
结题年份:
2021
批准年份:
2017
项目状态:
已结题
项目参与者:
薛如意、张春翌、张艳、唐文清、赵广西、孙达龙、马丽杰、李耀华
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
客服二维码
微信扫码咨询
中文摘要
肝癌居高不下的发病率和死亡率归结于癌细胞的增殖、侵袭和转移等恶性特征,也即细胞失极性的外在表现。Par3是Par极性复合物(Par3-Par6-aPKC)的中心分子,在不同组织或同一组织不同病理类型肿瘤中,Par3可发挥抑癌或促癌不同效应。与Par3调节细胞紧密连接(TJ)的功能有关。既往研究对Par3在肝癌中表达高/低,促癌/抑癌,结论矛盾。我们前期工作发现,Par3抑制肝癌发生发展。敲除小鼠肝脏Par3表达,未见TJ明显破坏,而发现1)肝细胞窦状隙面异常2)线粒体异常,提示Par3可能通过不依赖TJ的途径,而是通过调节肝细胞窦状隙面及线粒体功能参与肝癌发生发展。本项目拟结合使用转基因小鼠、活细胞实时成像等实验手段,深入研究Par3通过肝细胞窦状隙面和线粒体功能调控肝癌进程,及肝癌中Par3下调的分子机制。以期揭示肝癌发生发展新的分子机制,并因此提供新的诊治思路和靶标。
英文摘要
Cell polarity is essential in many biological processes and is also required for development as well as maintenance of tissue integrity. Loss of polarity is considered both a hallmark and precondition for human cancer. Hepatocellular carcinoma (HCC) is the primary cancer of the liver’s parenchyma and is the most common form of hepatic cancer. Aberrant expression of polarity proteins is closely associated with HCC development.. Three evolutionarily conserved protein complexes, Par, Scribble and Crumbs, are the key factors responsible for establishment of the apico-basal polarity. Among these complexes, Par has the widest range of functions. Par3 is the central component of the Par complex which consists of Par3, Par6 and an atypical protein kinase C. Par3 is also suggested as a tumor suppressor or pro-tumorigenic protein in different types of cancer. Conditional Par3 knockout in mouse skin delays the formation of Ras-induced papillomas due to reduced cell proliferation and increased apoptosis, suggesting a tumor-promoting role of Par3. However, the same condition predisposes skin to develop another type of cancer termed keratoacanthoma, con¬sistent with a tumor-suppressing function for Par3. Collectively, current data support an important role for Par3 in tumor progression and metastasis, although the specific mechanisms are context dependent.. The current studies from different groups found contradictory role of Par3 in HCC. For instance, Fang et al. reported that atypical PKC-binding domain deleted isoforms of asip, the human homolog of Par3, were downregulated in HCC. Whereas, Liou group found that the expression of Par-3 was increased in HCC and metastatic HCC specimens. Par-3 overexpression was significantly associated with extrahepatic metastasis and worse overall survival in HCC. The detailed molecular mechanisms of Par3 in HCC are still not clear. It was well known that Par polarity complex regulates cancer cell invasion and metastasis by controlling tight junction (TJ) assembly. In our preliminary experiments, we found that Par3 is downregulated in HCC and metastatic HCC specimens. Downregulation of Par3 induced cell proliferation, invasion and metastasis in vivo. However, we found that loss of APC didn’t show apparent TJ disruption, but led to dysfunctions of sinusoidal domains, such as increased local vacuoles and number of sinusoids, number of mitochondria, and severe swelling in mitochondria through electron microscopic and HE staining. These data suggested that Par3 might inhibited HCC development in a TJ independent pathway.. In this proposal, we plan to investigate the molecular connections and downstream signal pathways of Par3 and HCC development including Par3 regulated sinusoidal domain polarity, mitochondrial defects, and to further uncover the molecular mechanisms involved in decreased expression of Par3 in HCC. We will employ a multidiscipline approaches encompassing mouse genetics, time-lapse imaging, biochemistry and molecular biology and will use rodent as a model to pursue our aims above. The proposed studies in this application will not only allow us to advance the knowledge of molecular mechanisms in HCC, but may also produce new leads to diagnose and treat HCC.
肝癌居高不下的发病率和死亡率归结于癌细胞的增殖、侵袭和转移等恶性特征,也即细胞失极性的外在表现。Par3是Par极性复合物(Par3-Par6-aPKC)的中心分子,在不同组织或同一组织不同病理类型肿瘤中,Par3可发挥抑癌或促癌不同效应。既往研究对Par3在肝癌中表达高/低,促癌/抑癌,结论矛盾。本项目构建肝癌动物模型,结合使用转基因小鼠、免疫组织化学、生物化学与分子生物学等实验手段,在以往研究工作的基础上,我们发现,Par3肝特异性敲除的小鼠(Alb-Cre;Par3-/-)随年龄增长,出现肝脏相关疾病,血管增生及微环境改变,11月龄小鼠自发肝癌。已验证发现了与Par3有相互作用的新的蛋白分子,如Yap等。本项目在体内外实验进一步明确Par3抑制肝癌发生发展表型,及其分子机制。找到了介导细胞内信号通路的关键分子,为治疗肝癌提供了新的思路。
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
DOI:10.1016/j.jbc.2021.100730
发表时间:2021-01
期刊:The Journal of biological chemistry
影响因子:--
作者:Wang XX;Zhang S;Dong PP;Li YH;Zhang L;Shi SH;Yu ZQ;Chen S
通讯作者:Chen S
Loss of polarity protein Par3, via transcription factor Snail, promotes bladder cancer metastasis.
通过转录因子 Snail 丧失极性蛋白 Par3 可促进膀胱癌转移
DOI:10.1111/cas.14920
发表时间:2021-07
期刊:Cancer science
影响因子:5.7
作者:Wang S;Cai J;Zhang S;Dong M;Zhang L;Xu Y;Shen B;Chen S
通讯作者:Chen S
The long non-coding RNA DKFZp434J0226 regulates the alternative splicing process through phosphorylation of SF3B6 in PDAC.
长非编码 RNA DKFZp434J0226 通过 PDAC 中 SF3B6 的磷酸化调节选择性剪接过程
DOI:10.1186/s10020-021-00347-7
发表时间:2021-08-28
期刊:Molecular medicine (Cambridge, Mass.)
影响因子:--
作者:Li J;Tong H;Li D;Jiang Q;Zhang Y;Tang W;Jin D;Chen S;Qin X;Zhang S;Xue R
通讯作者:Xue R
Exosomes isolated from CAPS1overexpressing colorectal cancer cells promote cell migration
从过表达CAPS1的结直肠癌细胞中分离的外泌体促进细胞迁移
DOI:10.3892/or.2019.7361
发表时间:2019
期刊:Oncology Reports
影响因子:4.2
作者:Wu Bingrui;Sun Dalong;Ma Lijie;Deng Yiran;Zhang Si;Dong Ling;Chen She
通讯作者:Chen She
Activation of Platelet NLRP3 Inflammasome in Crohn's Disease.
克罗恩病中血小板 NLRP3 炎性体的激活
DOI:10.3389/fphar.2021.705325
发表时间:2021
期刊:Frontiers in pharmacology
影响因子:5.6
作者:Zhang G;Chen H;Guo Y;Zhang W;Jiang Q;Zhang S;Han L;Chen S;Xue R
通讯作者:Xue R
CAPS1通过调控磷酸戊糖途径影响肝癌转移的分子机制研究
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    54.7万元
  • 批准年份:
    2021
  • 负责人:
    陈舌
  • 依托单位:
极性蛋白Par3调控翻译起始参与结直肠癌发生发展的分子机制研究
  • 批准号:
    81972294
  • 项目类别:
    面上项目
  • 资助金额:
    55.0万元
  • 批准年份:
    2019
  • 负责人:
    陈舌
  • 依托单位:
Dasm1调控神经树突发育的机制研究
  • 批准号:
    81371268
  • 项目类别:
    面上项目
  • 资助金额:
    70.0万元
  • 批准年份:
    2013
  • 负责人:
    陈舌
  • 依托单位:
国内基金
海外基金